OPKO Health Inc banner

OPKO Health Inc
NASDAQ:OPK

Watchlist Manager
OPKO Health Inc Logo
OPKO Health Inc
NASDAQ:OPK
Watchlist
Price: 1.2 USD -2.44% Market Closed
Market Cap: $910.9m

P/OCF

-5.1
Current
20%
Cheaper
vs 3-y average of -6.4

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
-5.1
=
Market Cap
$895.7m
/
Operating Cash Flow
$-178.5m

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
-5.1
=
Market Cap
$895.7m
/
Operating Cash Flow
$-178.5m

Valuation Scenarios

OPKO Health Inc is trading above its industry average

If P/OCF returns to its Industry Average (16.6), the stock would be worth $-3.92 (426% downside from current price).

Statistics
Positive Scenarios
0/2
Maximum Downside
-426%
Maximum Upside
No Upside Scenarios
Average Downside
394%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple -5.1 $1.2
0%
Industry Average 16.6 $-3.92
-426%
Country Average 13.3 $-3.14
-361%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close
Market Cap P/OCF P/E
US
OPKO Health Inc
NASDAQ:OPK
910.9m USD -5.1 -4
FR
Pharnext SCA
OTC:PNEXF
6T USD -211 714.7 -160 127.7
US
Abbvie Inc
NYSE:ABBV
348.9B USD 18.3 83.4
US
Amgen Inc
NASDAQ:AMGN
183.4B USD 18.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
158.5B USD 15.8 18.6
US
Epizyme Inc
F:EPE
94.1B EUR -531.3 -533.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
108.2B USD 29.8 27.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 15.8 17.5
NL
argenx SE
XBRU:ARGX
41.9B EUR 120 37.5
US
Seagen Inc
F:SGT
39.3B EUR -85.8 -61.8
AU
CSL Ltd
ASX:CSL
63.6B AUD 11.7 30.3
P/E Multiple
Earnings Growth PEG
US
OPKO Health Inc
NASDAQ:OPK
Average P/E: 34.1
Negative Multiple: -4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83.4
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
23.8
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.4
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
14%
1.2
NL
argenx SE
XBRU:ARGX
37.5
30%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
30.3
9%
3.4

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 9 488 companies
0th percentile
-5.1
Low
0 — 8.8
Typical Range
8.8 — 20.1
High
20.1 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 8.8
Median 13.3
70th Percentile 20.1
Max 3 188 432.5

OPKO Health Inc
Glance View

In the bustling world of healthcare and biotechnology, OPKO Health Inc. stands as a unique and dynamic player. Founded by the ambitious mind of Dr. Phillip Frost, the company has woven itself into the fabric of diverse biomedical sectors. OPKO predicates its enterprise on the integration of complementary businesses ranging from diagnostics to pharmaceuticals, creating synergies that are not just theoretical, but markedly operational. At the heart of its operations lies the interplay between new drug discovery and diagnostics development, allowing OPKO to leverage cutting-edge technologies in crafting novel health solutions. By honing in on significant medical unmet needs, they aspire to deliver innovations that address chronic diseases such as diabetes, oncology, and neurological disorders. This strategic weaving together of distinct healthcare sectors manifests in OPKO's sprawling portfolio—from the renowned Rayaldee, which targets secondary hyperparathyroidism, to its advanced diagnostics segments, which include proprietary tests for specific cancers and other conditions. The company's revenue streams can be best visualized as an interlocking lattice of healthcare services and products. It earns through a blend of product sales, licensing, and collaborative agreements with other biotech and pharmaceutical giants. Rayaldee, as a potent testament to their R&D prowess, contributes robustly to their revenue, while the diagnostics division, powered by their substantial investment in technology and infrastructure, brings in consistent sales from various testing services. The company’s BioReference Laboratories, one of the largest full-service diagnostic laboratories in the U.S., also plays a critical role in their financial architecture, offering both routine and esoteric tests. Additionally, OPKO is involved in strategic collaborations and licensing arrangements, enhancing its market footprint and creating channels for revenue infusion through partnerships with industry leaders. Ultimately, OPKO Health Inc.'s narrative is one of leveraging diversified capabilities and strategic partnerships to carve out a formidable presence in the complex landscape of global healthcare.

OPK Intrinsic Value
1.18 USD
Overvaluation 1%
Intrinsic Value
Price $1.2
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett